Clinical trials: Congestive Heart Failure Chronic
Chronic Heart Failure
A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
The purpose of this study is to assess the safety, efficacy and optimal dose of TSG-01, an innovative drug with ginsenosides as its main components, in the treatment of patients with chronic heart failure(CHF).
- Trial name
- NCT04515290
- Testing
- TSG-01
- Where
- 5 sites in China
- Volunteers
- 85 people
- Sponsor
- Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
Heart Failure
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium.
- Trial name
- NCT01130597
- Testing
- patiromer, spironolactone
- Where
- 13 sites in Georgia, Slovenia
- Volunteers
- 63 people
- Sponsor
- Relypsa, Inc.
Chronic Systolic Heart Failure
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release…
- Trial name
- FIRST (NCT02188082)
- Testing
- IvabRadine hemisulfate Sustained-release Tablets
- Where
- 12 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure
Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the…
- Trial name
- OSICAT (NCT02068118)
- Testing
- Telecardiology program
- Where
- 38 sites in France, Martinique
- Volunteers
- 990 people
- Sponsor
- CDM e-Health
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)
The purpose of this clinical research study is to evaluate the safety and effectiveness of the investigational implantable hemodynamic monitor (IHM), and of the IHM in combination with an implantable cardioverter defibrillator…
- Trial name
- REDUCEhf (NCT00354159)
- Testing
- Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)
- Where
- 52 sites in United States
- Volunteers
- 442 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Congestive
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of 40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular ejection fraction on radionuclide…
- Trial name
- NCT00240292
- Testing
- Rosuvastatin
- Where
- 13 sites in Australia
- Volunteers
- 160 people
- Sponsor
- AstraZeneca
COPD, Asthma
Cardiorespiratory Diagnostic Study
This study uses a new breathing device called 'N-Tidal C' handset which measures breathing patterns. Investigators have found that people with cardiac and respiratory illnesses breathe out a gas, called carbon dioxide (CO2), in a…
- Conditions
- COPD, Asthma, Lung Cancer, Anemia
- Trial name
- CARES (NCT04939558)
- Testing
- N-Tidal C handset
- Where
- United Kingdom
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- TidalSense
Heart Failure
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care.
- Trial name
- PAS (NCT03970343)
- Testing
- OPTIMIZER Smart System
- Where
- 90 sites in United States
- Volunteers
- 620 people
- Sponsor
- Impulse Dynamics
Heart Failure
ALLEVIATE-HFrEF Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using…
- Trial name
- NCT05133089
- Testing
- ALV1 System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer
Heart Failure, Acute Heart Failure
PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days…
- Trial name
- NCT03161158
- Testing
- CHIARA-System, Usual care IV diuretics
- Where
- 11 sites in Germany, Sweden
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Chronic Heart Failure
Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure
Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a role in the development and progression of heart failure.
- Trial name
- BENEFICIAL (NCT00739687)
- Testing
- ALT-711
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Synvista Therapeutics, Inc
Acute MI, Heart Failure
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and…
- Conditions
- Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
- Trial name
- CHAPERONE-CKM (NCT07403669)
- Testing
- CHAPERONE AI, CKMiq AI, Quality of Life
- Where
- 5 sites in United States, Sweden
- Volunteers
- 300 people
- Sponsor
- Aventyn, Inc.
Heart Failure
V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.
- Trial name
- VECTOR-HF (NCT03775161)
- Testing
- V-LAP™ System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 45 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Heart Failure
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
- Trial name
- ARTS (NCT01345656)
- Testing
- BAY94-8862, Spironolactone
- Where
- 50 sites in Austria, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Bayer
Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
The INTERVENE-HF study is a prospective, non-randomized, multi-center (US only), investigational, feasibility study. The purpose of this study is to characterize safety of managing heart failure patients with integrated device…
- Trial name
- NCT02698241
- Testing
- Diagnostic & Medication Management
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals